Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Novo’s oral diabetes drug hits the mark again

The drug proves effective in reducing blood sugar in diabetes patients with renal impairment

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

- PMLiVE

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

Becomes the first checkpoint inhibitor for this indication

- PMLiVE

Envision Pharma Group relocates to support growth

Expands its Horsham to accommodate for additional team members

- PMLiVE

Evoke Group unveils new identity

Rebrands to help clients better navigate the healthcare landscape

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

How can pharma engage with key stakeholders on NHS service transformation?

Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change

Wilmington Healthcare

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

Armoured CAR ‘could overwhelm solid tumour resistance’

Eureka Therapeutics and Memorial Sloan Kettering approach shows promise

Medopad: the up and coming unicorn transforming remote patient monitoring

Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases.

Blue Latitude Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links